Table 3. Impact of baseline clinical parameters on NSCLC patients with de novo liver metastasis.
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| n | Event | OS (mo) | p value | Hazard ratio | p value | 95% CI | |
| Age, years | |||||||
| >60 | 34 | 30 | 8.8 | 0.555 | |||
| ≤ 60 | 41 | 38 | 8.8 | ||||
| BMI | |||||||
| >22 | 41 | 36 | 11.4 | 0.166 | |||
| ≤ 22 | 34 | 32 | 7.4 | ||||
| Sex | |||||||
| Male | 29 | 27 | 8.3 | 0.901 | |||
| Female | 46 | 41 | 9.0 | ||||
| DM | |||||||
| Yes | 8 | 8 | 9.5 | 0.899 | |||
| No | 67 | 60 | 8.8 | ||||
| Smoking history | |||||||
| Never | 54 | 49 | 9.0 | 0.781 | |||
| Former/current | 21 | 19 | 6.9 | ||||
| Performance status | |||||||
| ECOG 0–2 | 66 | 59 | 9.5 | 0.001 | <0.001 | 2.478–18.802 | |
| ECOG 3–4 | 9 | 9 | 1.5 | 6.83 | |||
| EGFR mutation | |||||||
| Yes | 39 | 35 | 11.9 | 0.155 | |||
| No | 36 | 33 | 7.7 | ||||
| Tumor type | |||||||
| ADC | 65 | 58 | 8.7 | 0.325 | |||
| Non-ADC | 10 | 10 | 8.8 | ||||
| LMR | |||||||
| >3.1 | 29 | 24 | 12.8 | 0.036 | 0.033 | 1.061–4.166 | |
| ≤3.1 | 45 | 43 | 7.4 | 2.10 | |||
| Extrahepatic metastasis | |||||||
| Yes | 69 | 62 | 8.7 | 0.417 | |||
| No | 6 | 6 | 17.1 | ||||
ADC, adenocarcinoma; BMI, body mass index; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; LMR, lymphocyte-to-monocyte ratio; mo, months; NSCLC, non-small-cell lung cancer; OS, overall survival.